SCHEMBL6288433

SCHEMBL6288433

COc1ccc(CCNc2nc(-c3ccc(OC)c(OC)c3)nn3c(C4CCCC4)nc(C)c23)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 3/20 0.42
POLB P06746 2/20 0.42
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
APP P05067 2/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 2/20 0.41
HIF1A Q16665 1/20 0.41
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6291353 0.87 ALDH1A1 (0.40) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL6288424 0.82 ABCG2 (0.45) KDM4EALDH1A1HPGDKMT2AMEN1
SCHEMBL6288393 0.80 ALDH1A1 (0.42) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL6288564 0.80 ABCG2 (0.43) MAPTKDM4EALDH1A1HPGDKMT2A
SCHEMBL6291841 0.79 MAPT (0.43) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL6291400 0.79 ALDH1A1 (0.41) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL6291395 0.79 BCL6 (0.42) MAPTKDM4EALDH1A1HPGDKMT2A
SCHEMBL6291390 0.78 ABCG2 (0.51) MAPTKDM4EALDH1A1HPGDKMT2A
SCHEMBL6288414 0.78 ALDH1A1 (0.42) MAPTKDM4EALDH1A1HPGDKMT2A
SCHEMBL14207219 0.75 BCL6 (0.40) MAPTKDM4EALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936609-B2 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2005-08-30 US disclosed
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2004-12-09 US disclosed
EP-1404677-A1 IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-07 EP disclosed
WO-2003000693-A1 IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors PDE3A, PDE2A, PDE4A MAPT 1159/4885KDM4E 2229/4885ALDH1A1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.